ABOUT US
38 Years of Innovation
Pioneering the Cell Death Approach
How can we directly measure how a patient’s tumor responds to treatment before treatment begins?
That question inspired the development of a laboratory method that tests living tumor cells against a broad range of drugs. Rather than predicting outcomes, this process observes how real tumor cells behave under controlled treatment conditions.
This work led to the development of CytoVantage 3D™, a functional oncology platform designed to identify which therapies show the greatest activity against an individual patient’s tumor. By combining live-cell testing with translational analysis, Cytometric Therapeutics bridges the gap between laboratory discovery and clinical decision-making.
Cytometric Therapeutics applies CytoVantage 3D to discover, validate, and advance new therapeutic candidates. By integrating laboratory data, computational analysis, and clinical readiness, we are defining a new model of cancer research where results are seen, measured, and acted upon.
With its first clinical program advancing toward human studies, Cytometric Therapeutics continues to expand its research capabilities and partnerships in oncology and drug discovery. Our teams in New York and California share a single goal: to translate functional precision into therapies that improve outcomes for patients facing the most difficult cancers.
Cytometric Therapeutics is built on curiosity, integrity, and shared discovery. We seek individuals who value collaboration and believe that rigorous science and compassion belong in the same room.
Behind every advancement is a group of researchers and leaders committed to translating precision into progress. Our leadership combines decades of experience in oncology, cytometry, and translational medicine — guiding a culture where ideas move freely from the lab to the clinic.